Infections in infants fed formula supplemented with bovine milk fat globule membranes

J Pediatr Gastroenterol Nutr. 2015 Mar;60(3):384-9. doi: 10.1097/MPG.0000000000000624.

Abstract

Objectives: Observational studies have shown that even in high-income countries formula-fed infants have a higher incidence of acute otitis media (AOM), and gastrointestinal and respiratory tract infections during the first year of life compared with breast-fed infants. We hypothesized that components of the milk fat globule membrane (MFGM) may be responsible for some of these differences and that supplementation with bovine MFGM would decrease the infectious morbidity in formula-fed infants.

Methods: In a double-blind randomized controlled trial, 160 formula-fed infants received experimental formula (EF) supplemented with bovine MFGM (EF) or unsupplemented standard formula (SF) from <2 months until 6 months of age. A breast-fed reference group consisted of 80 infants. Disease symptoms, health care contacts, and medication were recorded by the parents until 12 months of age. Serum immunoglobulin G for 10 pneumococcal serotypes was analyzed at 6 months of age.

Results: The cumulative incidence of AOM during the intervention was lower in the EF group than in the SF group (1% vs 9%, P = 0.034), and did not differ from the breast-fed reference group (0%, P = 1.0). The incidence (25% vs 43%, P = 0.021) and longitudinal prevalence (P = 0.012) of antipyretic use were significantly lower in the EF group than in the SF group. Serum immunoglobulin G concentrations against pneumococcal serotypes 1, 5, and 14 were lower in the EF group than in the SF group.

Conclusions: Supplementation of formula with bovine MFGM reduces the risk of AOM, decreases antipyretics use in formula-fed infants, and has immunomodulatory effects on humoral response against pneumococcus vaccine.

Trial registration: ClinicalTrials.gov NCT00624689.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Infective Agents / therapeutic use
  • Antipyretics / therapeutic use
  • Cattle
  • Child Development
  • Double-Blind Method
  • Food, Preserved / analysis*
  • Gastroenteritis / drug therapy
  • Gastroenteritis / epidemiology
  • Gastroenteritis / immunology
  • Gastroenteritis / prevention & control
  • Glycolipids / therapeutic use*
  • Glycoproteins / therapeutic use*
  • Humans
  • Immunomodulation*
  • Incidence
  • Infant
  • Infant Formula / chemistry*
  • Infant Nutritional Physiological Phenomena*
  • Longitudinal Studies
  • Otitis Media / drug therapy
  • Otitis Media / epidemiology
  • Otitis Media / immunology
  • Otitis Media / prevention & control*
  • Pneumococcal Infections / drug therapy
  • Pneumococcal Infections / epidemiology
  • Pneumococcal Infections / immunology
  • Pneumococcal Infections / prevention & control
  • Prevalence
  • Respiratory Tract Infections / drug therapy
  • Respiratory Tract Infections / epidemiology
  • Respiratory Tract Infections / immunology
  • Respiratory Tract Infections / prevention & control*
  • Risk
  • Sweden / epidemiology

Substances

  • Anti-Infective Agents
  • Antipyretics
  • Glycolipids
  • Glycoproteins
  • milk fat globule

Associated data

  • ClinicalTrials.gov/NCT00624689